Switch to adalimumab in patients with Cr
โ
Van Assche, G.; Vermeire, S.; Ballet, V.; Gabriels, F.; Noman, M.; D'Haens, G.;
๐
Article
๐
2011
๐
BMJ Publishing Group
๐
English
โ 356 KB
## Background: Elective switching between anti-tumour necrosis factor (tnf) agents not necessarily dictated by efficacy or tolerability occurs in clinical practice. a study was undertaken to evaluate prospectively the impact of elective switching of patients with crohn's disease well controlled wit